Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lutetium-177-PSMA in Oligo-metastatic Hormone Sensitive Prostate Cancer
2023-509881-39-00Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Jul 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of lutetium lu 177 vipivotide tetraxetan in prostate cancer (PCa) (2 arms), sponsored by Radboud University Medical Center. Primary endpoints: Fraction of patients with disease progression within 6 months and Time to disease progression and meeting EOT1 criteria. Started Jul 2024; status: completed.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2023-509881-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509881-39-00.